Country | Drug | Marginal rate | Rate among RS | Rate among RR |
Malawi (n=1306) | inh | 0.059934773 | 0.059170238 | 0.953801243 |
pza | 0.002312689 | 0.00143748 | 0.604323538 | |
levo | 0.332229513 | 0.000987495 | 0.04591181 | |
eth | 0.001561275 | 0.001433552 | 0.591521511 | |
amk | 0.001153572 | 0.001219703 | 0.053332609 | |
Peru (n=1521) | inh | 0.785727962 | 0.319883165 | 0.998016335 |
pza | 0.510782921 | 0.012295295 | 0.769380662 | |
levo | 0.014006169 | 0.003433835 | 0.025017803 | |
eth | 0.100353909 | 0.007756687 | 0.275508661 | |
amk | 0.131165041 | 0.003021112 | 0.20217046 | |
South Africa (n=3134) | inh | 0.089473806 | 0.011921494 | 0.744976366 |
pza | 0.046586938 | 0.000907021 | 0.529110114 | |
levo | 0.004237415 | 0.000526719 | 0.115334441 | |
eth | 0.331980635 | 0.000681881 | 0.483917188 | |
amk | 0.03351661 | 0.000618103 | 0.321291162 | |
UK (n=2831) | inh | 0.170545707 | 0.07691368 | 0.994410445 |
pza | 0.070964151 | 0.007197103 | 0.566614186 | |
levo | 0.003513319 | 0.001042214 | 0.059629102 | |
eth | 0.001127271 | 0.000921368 | 0.032878898 | |
amk | 0.010185639 | 0.000767618 | 0.136479073 | |
Viet Nam (n=1338) | inh | 0.244019439 | 0.24518451 | 0.973428345 |
pza | 0.011843812 | 0.003158774 | 0.441460286 | |
levo | 0.002709138 | 0.002490106 | 0.032201895 | |
eth | 0.002277654 | 0.002339351 | 0.041001766 | |
amk | 0.001149033 | 0.001205602 | 0.023756816 |
The first column indicates the country and number of input isolates, remaining columns are as follows: mean resistance rate estimate after Gibbs bias-correction and outbreak correction (reported as per cent), mean resistance rate estimate among rifampin-resistant (RR) isolates after outbreak correction (reported as per cent), mean resistance rate estimate among rifampin susceptible (RS) isolates after outbreak correction (reported as per cent). Top five countries chosen based on most input isolate sequences of greater or equal to 1306 isolates.
amk, amikacin; eth, ethionamide; inh, isoniazid; levo, levofloxacin; pza, pyrazinamide.